ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tizanidine

Also written as “Tizanidine”, “Zanaflex Capsules” and “tizanidine 8 mg”.

Its studies are mostly in Muscle Spasticity · Cognitive Dysfunction · Melanoma · Multiple Sclerosis · Cerebral Palsy, led by 4 companies.

Drug pageTizanidine: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 27, 20068 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Teva Pharmaceutical Industriesits history only30 open or runningphase 2since Jul 27, 2006Feb 2, 2006none ahead
Acorda Therapeutics20 open or runningphase 2since Apr 22, 2013Jul 25, 2011none ahead
Dr. Reddy's Laboratoriesits history only20 open or runningphase 1since Feb 8, 2010Feb 8, 2010none ahead
Elan Pharmaceuticalsits history only10 open or runningphase 3since Oct 8, 2002Oct 8, 2002none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Acorda Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 25, 2011First study: phase 1 study in Spasticity Due to Cerebral PalsyFirst studyNCT01405950 · 10 enrolled · United States
  2. Apr 22, 2013Phase 2 study in Muscle SpasticityNCT01839279 · 136 enrolled · United States

TargetBeta

“Adrenergic receptor alpha-2 agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
brimonidineruleAbbViephase 454
DexmedetomidinerulePfizerphase 446
OxymetazolineruleAbbViephase 420
Phentolamineruleopus-genetics-incphase 418
Epinephrinerulenasus-pharmaphase 417
Clonidinerulepharmafinaphase 45
lofexidineruleuswm-llc-dba-us-worldmedsphase 315

Studies

All 2 Acorda Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01839279Muscle Spasticity · United States2CompletedFeb 2014136
NCT01405950Spasticity Due to Cerebral Palsy · United States1TerminatedMar 201210

How it is read

Names in the registry

  • “Tizanidine”, 4 entries
  • “Zanaflex Capsules”, 4 entries
  • “tizanidine 8 mg”, 1 entry
  • “tizanidine 8mg”, 1 entry
  • “tizanidine hydrochloride capsule”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.